New perspectives in ovarian cancer treatment

Maturitas

Volumn 77, Issue 2, 2014, Pages 128-136

  Schmid, Bernd C ^a   Oehler, Martin K ^a,b  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Anti angiogenic therapy; Immunotherapy; Intraperitoneal chemotherapy; Ovarian cancer; PARP inhibitors; Targeted therapy

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FOLATE RECEPTOR 1; FOLIC ACID ANTAGONIST; FULVESTRANT; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; VASCULOTROPIN ANTIBODY;

CANCER CHEMOTHERAPY; CANCER THERAPY; CLINICAL STUDY; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOTHERAPY; OVARY CANCER; OVERALL SURVIVAL; REVIEW;

ANTI-ANGIOGENIC THERAPY; IMMUNOTHERAPY; INTRAPERITONEAL CHEMOTHERAPY; OVARIAN CANCER; PARP INHIBITORS; TARGETED THERAPY;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMMUNOTHERAPY; INFUSIONS, PARENTERAL; OVARIAN NEOPLASMS;

EID: 84893636462     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2013.11.009     Document Type: Review

References (115)

1. J.S.H. Ferlay, F. Bray, D. Forman, C. Mathers, and D.M. Parkin GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet] 2008
2. A. Jemal, R. Siegel, and E. Ward et al. Cancer statistics, 2008 CA: A Cancer Journal for Clinicians 58 March-April (2) 2008 71 96
3. P. Dinh, P. Harnett, M.J. Piccart-Gebhart, and A. Awada New therapies for ovarian cancer: cytotoxics and molecularly targeted agents Critical Reviews in Oncology/Hematology 67 August (2) 2008 103 112
4. D.J.J. Tewari, R. Salani, and D. Armstrong et al. Long-term survival advantage of intraperitoneal chemotherapy treatment in advanced ovarian cancer: an analysis of a Gynecologic Oncology Group ancillary data study (GOG#114/172, abstract) Society of gynecologic oncology annual meeting on women's cancer 2013 March 9-12, Los Angeles, CA 2013
5. W. Solass, R. Kerb, and T. Murdter et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy Annals of Surgical Oncology 2013, Sep 5 [Epub ahead of print]
6. R.J. Kurman, and M. Shih Ie The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory American Journal of Surgical Pathology 34 March (3) 2010 433 443
7. C. Ricciardelli, and M.K. Oehler Diverse molecular pathways in ovarian cancer and their clinical significance Maturitas 62 March (3) 2009 270 275
8. K.A. Thomas Vascular endothelial growth factor, a potent and selective angiogenic agent Journal of Biological Chemistry 271 January (2) 1996 603 606
9. P. Carmeliet VEGF as a key mediator of angiogenesis in cancer Oncology 69 Suppl. 3 2005 4 10
10. R.K. Jain Antiangiogenic therapy for cancer: current and emerging concepts Oncology (Williston Park) 19 April (4 Suppl. 3) 2005 7 16
11. R.A. Burger, M.F. Brady, and M.A. Bookman et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer New England Journal of Medicine 365 December (26) 2011 2473 2483
12. T.J. Perren, A.M. Swart, and J. Pfisterer et al. A phase 3 trial of bevacizumab in ovarian cancer New England Journal of Medicine 365 December (26) 2011 2484 2496
13. G. Kristensen, T. Perren, W. Qian, J. Pfisterer, J. Ledermann, and F. Joly Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 29 S 2011 LBA5006
14. C. Aghajanian, S.V. Blank, and B.A. Goff et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 30 June (17) 2012 2039 2045
15. C.N.L. Aghajanian, B. Goff, A. Husain, and S.V. Blank Updated overall survival analysis in OCEANS, a randomized phase 3 trial of gemcitabine + carboplatin and bevacizumab or placebo followed by bevacizumab or placebo in platinum-sensitive recurrent epithelial ovarian, primary peritoneal or fallopian tube cancer ESMO annual meeting Vienna 2012
16. E. Pujade-Lauraine, F. Hilpert, and B. Weber et al. AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC) ASCO meeting abstracts, vol. 30, no. 18 (Suppl.) 2012 June 20 2012 LBA5002
17. http://clinicaltrials.gov/show/NCT00976911 [accessed 23.11.13].
18. European Medical Agency. Avastin - bevacizumab 2012. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Summary-of-opinion/human/ 000582/WC500132867.pdf (accessed 23.11.13).
19. D.E. Cohn, K.H. Kim, K.E. Resnick, D.M. O'Malley, and J.M. Straughn Jr. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 29 April (10) 2011 1247 1251
20. M. Eichbaum, C. Mayer, and R. Eickhoff et al. The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer BMC Cancer 11 2011 453
21. M. Friedlander, K.C. Hancock, and D. Rischin et al. A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer Gynecologic Oncology 119 October (1) 2010 32 37
22. http://clinicaltrials.gov/show/NCT01227928 [accessed 23.11.13].
23. http://clinicaltrials.gov/show/NCT01015118 [accessed 23.11.13].
24. http://clinicaltrials.gov/show/NCT00532194 [accessed 23.11.13].
25. J.T.J.P. Ledermann, F.A. Raja, and A. Embleton et al. Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial. European Cancer Congress 2013 (ECCO-ESMO-ESTRO); 30.09.2013 2013
26. L. Eklund, and P. Saharinen Angiopoietin signaling in the vasculature Experimental Cell Research 319 May (9) 2013 1271 1280
27. J. Folkman Angiogenesis: an organizing principle for drug discovery? Nature Reviews Drug Discovery 6 April (4) 2007 273 286
28. B.Y. Karlan, A.M. Oza, and G.E. Richardson et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 30 February (4) 2012 362 371
29. Trebananib boosts PFS in ovarian cancer Cancer Discovery 3 August (8) 2013 831
30. B. Monk Addition of Trebananib to Paclitaxel Significantly Increases Progression-free Survival in Women with Recurrent Epithelial Ovarian Cancer European Cancer Congress 2013 (ECCO-ESMO-ESTRO) 01.10.2013; Amsterdam, Netherlands 2013
31. http://clinicaltrials.gov/show/NCT01204749 [accessed 23.11.13].
32. http://clinicaltrials.gov/show/NCT01493505 [accessed 23.11.13].
33. H. Huang, A. Bhat, G. Woodnutt, and R. Lappe Targeting the ANGPT-TIE2 pathway in malignancy Nature Reviews Cancer 10 August (8) 2010 575 585
34. W. Schaefer, J.T. Regula, and M. Bahner et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies Proceedings of the National Academy of Sciences of the United States of America 108 July (27) 2011 11187 11192
35. J.A. Engelman Targeting PI3K signalling in cancer: opportunities, challenges and limitations Nature Reviews Cancer 9 August (8) 2009 550 562
36. K.T. Kuo, T.L. Mao, and S. Jones et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma American Journal of Pathology 174 May (5) 2009 1597 1601
37. http://clinicaltrials.gov/show/NCT01196429 [accessed 23.11.13].
38. F. Janku, J.J. Wheler, and S.N. Westin et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 30 March (8) 2012 777 782
39. M. Takano, H. Kouta, and N. Sasaki et al. Combination chemotherapy with temsirolimus and trabectedin in patients with heavily pretreated clear cell carcinoma of the ovary ASCO meeting abstracts 2013 June 17 2013 e16519
40. M. Zakikhani, M.J. Blouin, E. Piura, and M.N. Pollak Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells Breast Cancer Research and Treatment 123 August (1) 2010 271 279
41. J.M. Evans, L.A. Donnelly, A.M. Emslie-Smith, D.R. Alessi, and A.D. Morris Metformin and reduced risk of cancer in diabetic patients British Medical Journal 330 June (7503) 2005 1304 1305
42. S. Jiralerspong, S.L. Palla, and S.H. Giordano et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 27 July (20) 2009 3297 3302
43. M.J. MacKenzie, S. Ernst, C. Johnson, and E. Winquist A phase I study of temsirolimus and metformin in advanced solid tumours Investigational New Drugs 30 April (2) 2012 647 652
44. http://clinicaltrials.gov/show/NCT01529593 [accessed 23.11.13].
45. S. Hafsi, F.M. Pezzino, and S. Candido et al. Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review) International Journal of Oncology 40 March (3) 2012 639 644
46. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, and W.L. McGuire Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 January (4785) 1987 177 182
47. L.J. Tafe, and G.J. Tsongalis The human epidermal growth factor receptor 2 (HER2) Clinical Chemistry and Laboratory Medicine: CCLM/FESCC 50 January (1) 2012 23 30
48. J. Farley, S. Fuchiuji, and K.M. Darcy et al. Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study Gynecologic Oncology 113 June (3) 2009 341 347
49. M.A. Bookman, K.M. Darcy, D. Clarke-Pearson, R.A. Boothby, and I.R. Horowitz Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 21 January (2) 2003 283 290
50. S.P. Langdon, D. Faratian, Y. Nagumo, P. Mullen, and D.J. Harrison Pertuzumab for the treatment of ovarian cancer Expert Opinion on Biological Therapy 10 July (7) 2010 1113 1120
51. M.S. Gordon, D. Matei, and C. Aghajanian et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 24 September (26) 2006 4324 4332
52. S. Makhija, L.C. Amler, and D. Glenn et al. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 28 March (7) 2010 1215 1223
53. http://clinicaltrials.gov/show/NCT01684878 [accessed 23.11.13].
54. S.B. Kaye, C.J. Poole, and A. Danska-Bidzinska et al. A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 24 January (1) 2013 145 152
55. B. Tanner, D. Hasenclever, and K. Stern et al. ErbB-3 predicts survival in ovarian cancer Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 24 September (26) 2006 4317 4323
56. S. Wang, X. Huang, C.K. Lee, and B. Liu Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin Oncogene 29 July (29) 2010 4225 4236
57. http://clinicaltrials.gov/show/NCT01447706 [accessed 23.11.13].
58. F. Simpkins, A. Garcia-Soto, and J. Slingerland New insights on the role of hormonal therapy in ovarian cancer Steroids 78 June (6) 2013 530 537
59. F. Simpkins, P. Hevia-Paez, and J. Sun et al. Src inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 18 November (21) 2012 5911 5923
60. P.A. Argenta, S.G. Thomas, and P.L. Judson et al. A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer Gynecologic Oncology 113 May (2) 2009 205 209
61. J.F. Smyth, C. Gourley, and G. Walker et al. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients Clinical Cancer Research 13 12 2007 3617 3622
62. J.F. Smyth, C. Gourley, and G. Walker et al. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 13 June (12) 2007 3617 3622
63. A. Bowman, H. Gabra, and S.P. Langdon et al. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 8 July (7) 2002 2233 2239
64. P.T. Ramirez, K.M. Schmeler, and M.R. Milam et al. Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum Gynecologic Oncology 110 1 2008 56 59
65. A. Mukhopadhyay, N. Curtin, R. Plummer, and R.J. Edmondson PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine BJOG: An International Journal of Obstetrics and Gynaecology 118 March (4) 2011 429 432
66. V. Schreiber, F. Dantzer, J.C. Ame, and G. de Murcia Poly(ADP-ribose): novel functions for an old molecule Nature Reviews Molecular Cell Biology 7 July (7) 2006 517 528
67. H.E. Bryant, N. Schultz, and H.D. Thomas et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature 434 April (7035) 2005 913 917
68. N. Schultz, E. Lopez, N. Saleh-Gohari, and T. Helleday Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination Nucleic Acids Research 31 September (17) 2003 4959 4964
69. A. Ashworth A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 26 August (22) 2008 3785 3790
70. I. Martinek, K. Haldar, and K. Gaitskell et al. DNA-repair pathway inhibitors for the treatment of ovarian cancer Cochrane Database of Systematic Reviews 6 2010 CD007929
71. H.M. Shaw, and M. Hall Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib OncoTargets and Therapy 6 2013 1197 1206
72. J. Ledermann, P. Harter, and C. Gourley et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer New England Journal of Medicine 366 April (15) 2012 1382 1392
73. J.A. Ledermann, P. Harter, and C. Gourley et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm) ASCO meeting abstracts 2013 June 17 2013 5505
74. http://clinicaltrials.gov/show/NCT01874353 [accessed 23.11.13].
75. http://clinicaltrials.gov/show/NCT01445418 [accessed 23.11.13].
76. http://clinicaltrials.gov/show/NCT01237067 [accessed 23.11.13].
77. http://clinicaltrials.gov/show/NCT00516724 [accessed 23.11.13].
78. http://clinicaltrials.gov/show/NCT01650376 [accessed 23.11.13].
79. A.M. Oza, D. Cibula, and A. Oaknin et al. Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study Journal of Clinical Oncology 30 15 2012
80. http://clinicaltrials.gov/show/NCT01891344 [accessed 23.11.13].
81. http://clinicaltrials.gov/show/NCT00664781 [accessed 23.11.13].
82. http://clinicaltrials.gov/show/NCT01847274 [accessed 23.11.13].
83. H. Hirai, Y. Iwasawa, and M. Okada et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents Molecular Cancer Therapeutics 8 November (11) 2009 2992 3000
84. K. Mahajan, and N.P. Mahajan WEE1 tyrosine kinase, a novel epigenetic modifier Trends in Genetics 29 July (7) 2013 394 402
85. B.B. Zhou, and J. Bartek Targeting the checkpoint kinases: chemosensitization versus chemoprotection Nature Reviews Cancer 4 March (3) 2004 216 225
86. M. Molinari Cell cycle checkpoints and their inactivation in human cancer Cell Proliferation 33 October (5) 2000 261 274
87. http://clinicaltrials.gov/show/NCT01164995 [accessed 23.11.13].
88. http://clinicaltrials.gov/show/NCT01357161 [accessed 23.11.13].
89. L.E. Kelemen, M.T. Goodman, and V. McGuire et al. Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium Cancer Epidemiology, Biomarkers and Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 19 July (7) 2010 1822 1830
90. C. Heidelberger Chemical carcinogenesis, chemotherapy: cancer's continuing core challenges - G.H.A. Clowes Memorial Lecture Cancer Research 30 June (6) 1970 1549 1569
91. R. Hertz, M.C. Li, and D.B. Spencer Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma Proceedings of the Society for Experimental Biology and Medicine 93 November (2) 1956 361 366
92. D. Cardinale, G. Guaitoli, and D. Tondi et al. Protein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase Proceedings of the National Academy of Sciences of the United States of America 108 August (34) 2011 E542 E549
93. A.R. Hagemann, A.P. Novetsky, and I. Zighelboim et al. Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer Gynecologic Oncology 131 December 3, 2013 535 540
94. G. Toffoli, C. Cernigoi, A. Russo, A. Gallo, M. Bagnoli, and M. Boiocchi Overexpression of folate binding protein in ovarian cancers International Journal of Cancer Journal International Du Cancer 74 April (2) 1997 193 198
95. A. White, R. Coleman, and D. Armstrong et al. Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: final data from a multicenter phase II study Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 28 Suppl. 15 2010 5001
96. http://clinicaltrials.gov/show/NCT00849667 [accessed 22.11.13].
97. http://clinicaltrials.gov/show/NCT00738699 [accessed 22.11.13].
98. C.P. Leamon, and J.A. Reddy Folate-targeted chemotherapy Advanced Drug Delivery Reviews 56 8 2004 1127 1141
99. R.W. Naumann, R.L. Coleman, and R.A. Burger et al. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer Journal of Clinical Oncology 31 35 2013 4400 4406
100. http://clinicaltrials.gov/show/NCT01170650 [accessed 22.11.13].
101. G.M. van Dam, G. Themelis, and L.M.A. Crane et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-[alpha] targeting: first in-human results Nature Medicine 17 10 2011 1315 1319
102. P.J. Stiff, C. Czerlanis, and M.L. Drakes Dendritic cell immunotherapy in ovarian cancer Expert Review of Anticancer Therapy 13 January (1) 2013 43 53
103. O.E. Rahma, E. Ashtar, and M. Czystowska et al. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients Cancer Immunology, Immunotherapy 61 March (3) 2012 373 384
104. C.S. Chu, J. Boyer, and D.S. Schullery et al. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission Cancer Immunology, Immunotherapy 61 May (5) 2012 629 641
105. http://clinicaltrials.gov/show/NCT01068509 [accessed 23.11.13].
106. J.S.E.G. Goh, and H. Gray Clinical study of autologous dendritic cell therapy targeting mucin 1 for treatment of ovarian cancer patients in first remission European cancer congress 2013
107. J.S. Berek, J.C. Goh, H.J. Gray, J. Fiorica, and J.R. Mason A study of autologous dendritic cell therapy targeting mucin-1 for treatment of patients with epithelial ovarian cancer in first remission ASCO meeting abstracts 2012 May 30 2012 TPS5113
108. http://clinicaltrials.gov/show/NCT01521143 [accessed 23.11.13].
109. M.A. Morse, A.C. Hobeika, and T. Osada et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines Blood 112 August (3) 2008 610 618
110. W. Solass, U. Giger-Pabst, J. Zieren, and M.A. Reymond Pressurized intraperitoneal aerosol chemotherapy (PIPAC): occupational health and safety aspects Annals of Surgical Oncology 20 October (11) 2013 3504 3511
111. C.H. Heldin, K. Rubin, K. Pietras, and A. Ostman High interstitial fluid pressure - an obstacle in cancer therapy Nature Reviews Cancer 4 October (10) 2004 806 813
112. P. Esquis, D. Consolo, and G. Magnin et al. High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis Annals of Surgery 244 July (1) 2006 106 112
113. http://clinicaltrials.gov/show/NCT01809379 [accessed 23.11.13].
114. J.O. Gustafsson, M.K. Oehler, A. Ruszkiewicz, S.R. McColl, and P. Hoffmann MALDI imaging mass spectrometry (MALDI-IMS)-application of spatial proteomics for ovarian cancer classification and diagnosis International Journal of Molecular Sciences 12 1 2011 773 794
115. B.D. Smith, G.L. Smith, A. Hurria, G.N. Hortobagyi, and T.A. Buchholz Future of cancer incidence in the United States: burdens upon an aging, changing nation Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 27 June (17) 2009 2758 2765